Reduced Apelin levels in Stable Angina

Internal Medicine

Volumn 47, Issue 22, 2008, Pages 1951-1955

  Li, Zhao ^a   Bai, Yinglong ^a   Hu, Jian ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Coronary angiography; Gensini score; Peptide; Stenosis

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; APELIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGE; ARTICLE; BLOOD SAMPLING; BODY MASS; CHINA; CIGARETTE SMOKING; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; CORRELATION ANALYSIS; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; PATHOPHYSIOLOGY; PATIENT SELECTION; SCORING SYSTEM; SEX DIFFERENCE; STABLE ANGINA PECTORIS; UNIVERSITY HOSPITAL;

ANGINA PECTORIS; BIOLOGICAL MARKERS; CORONARY STENOSIS; CROSS-SECTIONAL STUDIES; DOWN-REGULATION; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED;

EID: 59849116214     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.47.1287     Document Type: Article

References (25)

1. Falcão-Pires I, Leite-Moreira AF. Apelin: a novel neurohumoral modulator of the cardiovascular system. Pathophysiologic importance and potential use as a therapeutic target. Rev Port Cardiol 24: 1263-1276, 2005.
2. Kleinz MJ, Davenport AP. Emerging roles of apelin in biology and medicine. Pharmacol Ther 107 (2): 198-211, 2005.
3. Zhong JC, Yu XY, Huang Y, Yung LM, Lau CW, Lin SG. Apelin modulates aortic vascular tone via endothelial nitric oxide synthase phosphorylation pathway in diabetic mice. Cardiovasc Res 1 74 (3): 388-395, 2007.
4. Hashimoto T, Kihara M, Ishida J, et al. Apelin stimulates myosin light chain phosphorylation in vascular smooth muscle cells. Arterioscler Thromb-Vasc Biol 26 (6): 1267-1272, 2006.
5. Mullens W, Bartunek J, Wilson Tang WH, et al. Early and late effects of cardiac resynchronization therapy on force-frequency relation and contractility regulating gene expression in heart failure patients. Heart Rhythm 5 (1): 52-59, 2008.
6. Hashimoto T, Kihara M, Imai N, et al. Requirement of apelin-apelin receptor system for oxidative stress-linked atherosclerosis. Am J Pathol 171 (5): 1705-1712, 2007.
7. Schwedhelm E, Bartling A, Lenzen H, et al. Urinary 8-isoprostaglandin F2 alpha as a risk marker in patients with coronary heart disease: a matched case-control study. Circulation 109 (7): 843-848, 2004.
8. Sullivan DR, Marwick TH, Freedman SB. A new method of scaring coronary angiograms to reflect extent of coronary atherosclerosis and improve correlation with major risk factors. Am Heart J 119: 1262-1267, 1990.
9. Gualillo O, Gonzalez-Juanatey JR, Lago F. The emerging role of adipokines as mediators of cardiovascular function: physiologic and clinical perspectives. Trends Cardiovasc Med 17 (8): 275-283, 2007.
10. Losano G, Penna C, Cappello S, Pagliaro P. Activity of apelin and APJ receptors on myocardial contractility and vasomotor tone. Review. Ital Heart J Suppl 6 (5): 272-278, 2005.
11. Katugampola SD, Kuc RE, Maguire JJ, Davenport AP. G-ptotein-coupled receptors in human atherosclerosis: comparison of vasoconstrictors (endothelin and thromboxane) with recently deorphanized (urotensin-II, apelin and ghrelin) receptors. Clin Sci (Lond) 103 Suppl 48: 171S-175S, 2002.
12. Goetze JP, Rehfeld JF, Carlsen J, et al. Apelin: a new plasma marker of cardiopulmonary disease. Regal Pept 133 (1-3): 134-138, 2006.
13. Ringqvist I, Fisher LD, Mock M, et al. Prognostic value of angiographic indices of coronary artery disease from the Coronary Artery Surgery Study (CASS). J Clin Invest 71 (6): 1854-1866, 1983.
14. Berry MF, Pirolli TJ, Jayasankar V, et al. Apelin has in vivo inotropic effects on normal and failing hearts. Circulation 110 (11 Suppl 1): II187-II193, 2004.
15. Grist O. Apelin and vascular dysfunction in type 2 diabetes. Cardiovasc Res 1 74 (3): 339-340, 2007.
16. Kadswaki S, Okamura T, Hozawa A, et al: Relationship of elevated casual blood glucose level with coronary heart disease, cardiovascular disease and all-cause mortality in a representative sample of the Japanese population. NIPPON DATA80. Diabetologia 16: 2008 [Epub ahead of print].
17. Tasci I, Dogru T, Naharci I, et al. Plasma apelin is lower in patients with elevated LDL-cholesterol. Exp Clin Endocrinol Diabetes 115 (7): 428-432, 2007.
18. Kagiyama S, Fukuhara M, Matsumura & Lin Y, Fujii K, Iida M. Central and peripheral cardiovascular actions of apelin in conscious rats. Regul Pept 125 (1-3): 55-59, 2005.
19. Mitra A, Katovich MJ, Mecca A, Rowland NE. Effects of central and peripheral injections of apelin on fluid intake and cardiovascular parameters in rats. Physiol Behav 89 (2): 221-225, 2006.
20. Masri B, Lahlou H, Mazarguil H, et al. Apelin (65-77) activates extracellular signal-regulated kinases via a PTX-sensitive G protein. Biochem Biophys Res Commun 290: 539-545, 2002.
21. Wang G, Anini Y, Wei W, et al. Apelin, a new enteric: peptide: localization in the gastrointestinal tract, ontogeny, and stimulation of gastric cell proliferation and of cholecystokinin secretion. Endocrinology 145: 1342-1348, 2004.
22. Gurzu B, Petrescu BC, Costuleanu M, Petrescu G. Interactions between apelin and angiotensin II on rat portal vein. J Renin Angiotensin Aldosterone Syst 7 (4): 212-216, 2006.
23. Smith CC, Mocanu MM, Bowen J, et al. Temporal changes in myocardial salvage kinases during reperfusion following ischemia: studies involving the cardioprotective adipocytokine apelin. Cardiovasc Drugs Ther 21 (6): 409-414, 2007.
24. De Mota N, Reaux-Le Goazigo A, El Messari S, et al. Apelin, a potent diuretic neuropeptide counteracting vasopressin actions through inhibition of vasopressin neuron activity and vasopressin release. Proc Natl Acad Sci U S A 101 (28): 10464-10469, 2004.
25. Jia YX, Lu ZF, Zhang J, et al. Apelin activates L-arginine/nitric oxide synthase/nitric oxide pathway in rat aortas. Peptides 28 (10): 2023-2029, 2007.